Overview

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

Status:
Not yet recruiting
Trial end date:
2022-04-22
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the dermal safety of Bemotrizinol (6%).
Phase:
Phase 2
Details
Lead Sponsor:
DSM Nutritional Products, Inc.
Treatments:
Ethanol
Petrolatum
Sunscreening Agents